Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Rafael starts trial of CPI-613 and mFFX for pancreatic cancer

CPI-613 is a drug developed by Rafael to target the altered regulation of metabolic processes of cancer cells. Credit: Photo by rawpixel on Unsplash.



  • Rafael Pharmaceuticals
Close
Close
Close

Go Top